Abstract Library

#4090 Octreotide infusion pump in patients with functional neuroendocrine tumors and refractory hormonal syndromes

Introduction: In patients with metastatic functional neuroendocrine tumors (NETs), symptoms are, sometimes, not adequately controlled with long-acting somatostatin analogues (LASSAs), so patients need to use boost subcutaneous (sc) octreotide injections (inj) daily. However, this approach is not always effective and convenient for the patients.

Conference:

Presenting Author: Thuringer J

Authors: Thuringer J, Parker G, Sarma A, Hayes A, Mandair D,

Keywords: carcinoid syndrome, VIPoma, Octreotide, pump, refractory, subcutaneous,

#3981 Identifying patients with undiagnosed small intestinal neuroendocrine tumors using statistical and machine learning: Model development and validation study

Introduction: Diagnosis of small intestinal neuroendocrine tumors (SI-NETs) is often delayed due to non-specific symptoms and lack of awareness among primary and secondary care physicians. Earlier diagnosis may lead to improved clinical and patient outcomes. Clinical prediction models using machine learning could present novel opportunities for expedited diagnosis in primary care.

Conference:

Presenting Author:

Authors: Clift A, Mahon H, Khan G, Boardman-Pretty F, Worker A,

Keywords: machine learning, artificial intelligence, diagnosis, neuroendocrine tumor,

#3972 Machine-learning identified optimised classification models for the diagnosis of typical and atypical lung carcinoids based on the genomic variance

Introduction: The current diagnosis of lung typical carcinoids (TCs) and atypical carcinoids (ACs) can be ambiguous for small biopsies containing limited tissues.

Conference:

Presenting Author: Guo Y

Authors: Guo Y, Su F, Hu S, Chen R, Chen Q,

Keywords: lung carcinoid, typical carcinoid, atypical carcinoid, machine-learning, diagnosis, genomic features,

#3882 Adjuvant therapy for pancreatic neuroendocrine tumors – Expert consensus and recommendations for future research

Introduction: With the increase of incidentally diagnosed pancreatic neuroendocrine tumors (panNEN), more patients are treated with curative intent. Survival in patients with a panNEN is impacted by the development of recurrence, but postoperative adjuvant therapy is not yet recommended in guidelines due to absence of evidence. Multiple clinicopathological characteristics have been described in literature to identify patients at high-risk of recurrence who might benefit from adjuvant treatment. Since panNEN are rare tumors, prospective randomized controlled studies on the role of adjuvant therapy in these patients have not been performed.

Conference:

Presenting Author: Heidsma C

Authors: Heidsma C, Engelsman A, Klümpen H, Falconi M, Frilling A,

Keywords: pancreatic neuroendocrine tumor, recurrence, adjuvant therapy, prevention, expert consensus, future research,

#3122 Plasma protein biomarkers for the detection of pancreatic neuroendocrine tumors (Pan-NET) and differentiation from small intestinal (SI) NET

Introduction: There is an unmet need for novel biomarkers to diagnose and monitor patients with Pan-NET and SI-NET.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Thiis-Evensen E

Authors: Thiis-Evensen E, Kjellman M, Knigge U, Gronbaek H, Schalin-Jäntti C,

Keywords: detection, Pan-NET, SI-NET, biomarker, plasma protein, machine learning,